Innovations • Global Impact • In The News • Our People

"A Day in The Life" at AAHI

AAHI is pleased to introduce you to our colleagues and their different perspectives, as we collaborate to support development of AAHI's immune-stimulating platform technologies. It takes a village to develop accessible vaccines for a safe and healthy world, free of life-threatening diseases.


The latest scientific breakthroughs at AAHI.

Snake antivenom is produced by injecting small amounts of venom in large mammals to simulate production of antibodies, which are harvested to make antivenom. Scientists at Instituto Clodomiro Picado in Costa Rica collaborated with AAHI to demonstrate that adjuvant formulations containing squalene oil are promising candidates to enhance antibody responses in horses in a study recently published in Toxicon. 

Researchers at the Swiss Tropical and Public Health Institute tested three different AAHI TLR 4 agonist adjuvant formulations – GLA-LSQ (including QS-21), GLA-Alum, and GLA-SE (including squalene) – in a preclinical bake-off. The study results, published in Malaria Journal, demonstrated that immunization with GLA-SE produced the most antigen-specific antibodies and in vitro parasite growth inhibition.

Make your products accessible to those who need them most. Collaborate with AAHI.



Collaboration across communities.

Explore AAHI's different areas of impact.

Heidelberg, Germany

AAHI's GLA-SE adjuvant formulation is a critical component in a new vaccine against blood stage malaria, SumayaVac-1

The preliminary results of a Phase 1 clinical trial evaluating SumayaVac-1, published in npj Vaccines, demonstrated that the vaccine candidate safely reduces malaria parasite burden and shows promise for long-lasting protection against blood stage malaria.

Seattle, Washington

AAHI announces support to develop a temperature stable, single dose chikungunya RNA vaccine candidate through human clinical trials

AAHI will develop a groundbreaking chikungunya RNA vaccine candidate that will generate a live "attenuated" virus to induce strong and long-lasting protection against the mosquito-borne disease, for which no approved vaccines currently exists, with the support of the National Institute of Health. The project supports the first-in-human evaluation of a dried (lyophilized) formulation of AAHI's RNA vaccine platform technology and will demonstrate the use of RNA vaccine technology to avoid problems posed by large-scale manufacture of live-attenuated viruses. AAHI will produce a dried RNA vaccine candidate against chikungunya, validated in humans and able to reach areas of the world, including Asia, Africa, and Latin America, in which chikungunya is endemic.

Help us make impossible vaccines possible.


What to know about the new COVID-19 variant and fall boosters

By Rolando Hernandez

OPB Think Out Loud

Dr. Corey Casper, CEO discusses emerging COVID-19 variants that may evade protection provided by currently available vaccines with Dave Miller on Oregon Public Broadcast's "Think Out Loud" talk show. Dr. Casper highlights the need to support development of new vaccine technologies that promise to provide broader, longer lasting protection without frequent boosters to chase the latest variant.

If you or someone you know is struggling to figure out how to best protect against the current surge in COVID-19 cases, trying to understand the new "Eris" variant of interest, or puzzling over when and if to get your COVID-19 booster, tune in today.

Formulation Innovation: thermostable vaccines, sustainable materials, & mucosal delivery

By Charlotte Baker

Vaccine Insights

Dr. Christopher Fox, SVP, Formulations, explains that his desire to make a real global impact motivates his innovation and development of effective, cost-efficient, and accessible vaccine formulations for sustainable and resilient vaccine infrastructure. He discusses the practical implications and challenges of developing formulations for real-world sustainability and accessibility.

"Now we are looking into what I think are even more important and impactful topics, like the sustainability of the raw materials that go into these formulations and how to make formulations thermostable, so they are accessible around the world." -Dr. Christopher Fox, SVP, Formulations


Collaboration across communities.

Explore our different areas of impact.

Featured Post

Dr. Reinhard Vehring will present encouraging results on the development of scaled-up manufacturing processes of AAHI's spray dried tuberculosis vaccine candidate, ID93 + GLA-SE, at this year's International Society for Aerosols in Medicine Congress 2023, the world's largest pulmonary drug delivery and respiratory health conferences.

Openings and Opportunities


The Scientist I/II/Senior Scientist will be responsible for broadening the applications of AAHI's RNA vaccine platform to a wide range of infectious disease and oncology targets and will lead a growing, multi-level, early development team to bring novel RNA vaccine candidates to the initiation of Phase 1 clinical trials. 


The Associate/Staff Scientist will be responsible for directing the in vivo mouse immunology studies on the RNA team, providing support to conduct in vivo aspects of product stability and release testing studies for AAHI's Product Development and GMP teams as necessary.

Learn more about our formulation technology

We partner with biotech leaders to develop vaccines and more.

Synthetic TLR4 ligand in squalene nanoemulsion

Synthetic TLR4 ligand in QS- 21 containing liposome

Synthetic TLR4 ligand in aqueous formulation

Dual agonist containing both TLR4 and TLR7/8 ligands

2nd-Gen synthetic TLR4 ligand
in squalene nanoemulsion

2nd-Gen synthetic TLR4 ligand
in QS-21 containing liposome

2nd-Gen synthetic TLR4 ligand
in aqueous formulation

Alum nanoparticle formulation, customized particle size

Synthetic TLR7/8 ligand in
squalene nanoemulsion

Synthetic TLR7/8 ligand
adsorbed to aluminum

Synthetic TLR7/8 ligand in
aqueous formulation

Nanostructured lipid carrier

See how our formulations are being used.